When Antidepressants Don’t Work: Next Steps for TRD

If you have tried two or more antidepressants at adequate doses for adequate time periods and still do not feel meaningfully better, you are not alone — and you have not failed. What you are experiencing has a clinical name: treatment-resistant depression. It is a recognized pattern in psychiatric medicine, not a character flaw or a sign that nothing will ever work. There are structured, evidence-based pathways designed specifically for this situation, and understanding what they involve is a reasonable, practical place to start.

What ‘Treatment-Resistant’ Actually Means Clinically

The term treatment-resistant depression, often abbreviated as TRD, has a specific clinical meaning. According to the Mayo Clinic, it generally refers to depression that has not responded adequately to at least two different antidepressant medications taken at appropriate doses for appropriate durations — typically six to eight weeks at minimum.

That definition matters for a few reasons. It tells you that a single medication trial that didn’t work doesn’t automatically meet the threshold. But it also clarifies that if you have gone through several trials without meaningful improvement, something more systematic is happening, and a more structured clinical approach is warranted.

It is also worth noting what TRD is not. It is not a permanent state. It does not mean depression is untreatable in your case. It means the initial treatment pathways — most commonly SSRIs and SNRIs — were not sufficient on their own, and that the next step requires a more thorough clinical evaluation and a broader set of tools.

The American Psychiatric Association recognizes TRD as a distinct clinical challenge within the broader category of major depressive disorder, and there are validated protocols for addressing it systematically. That structure is what gives this situation a path forward.

Why Depression Resists Standard Treatment: Contributing Factors

Understanding why antidepressants may not be working is not just an academic exercise — it directly informs what the next step should be. There is rarely a single explanation. More often, several factors are converging.

Biological and Genetic Variables

Individual differences in how the body metabolizes psychiatric medications play a significant role. Pharmacogenomic factors — essentially, how your specific genetic makeup processes certain drugs — can result in a medication being cleared too quickly or metabolized too slowly to produce a therapeutic effect. This is one reason the same antidepressant can work well for one person and produce no benefit for another at the same dose.

Diagnostic Accuracy

In some cases, antidepressants are not working because the underlying diagnosis is incomplete or inaccurate. Depression is a clinical syndrome with multiple subtypes, and conditions like bipolar disorder, dysthymia, or ADHD can present with significant depressive symptoms. Treating depression without identifying a co-occurring condition that is driving those symptoms often produces limited results. This is one of the most clinically important reasons a thorough diagnostic review is essential when antidepressants are not working.

Medical Conditions Running in the Background

Certain unaddressed medical conditions can sustain depressive symptoms regardless of psychiatric medication. Thyroid dysfunction, vitamin deficiencies, sleep disorders, and chronic inflammatory conditions are among the more common culprits. These are not always identified during brief primary care visits, and they can significantly limit how well any antidepressant performs.

Inadequate Trial Parameters

Not every antidepressant trial is clinically adequate. Stopping a medication after two or three weeks because side effects were uncomfortable, or taking a dose that was too low to be therapeutic, can lead to a false conclusion that the medication did not work. A careful review of previous trials — doses, duration, side effects, and actual adherence — is a meaningful part of any TRD evaluation. You can learn more about how those decisions are made in this overview of When to Adjust Psychiatric Medications: Clinical Guidelines.

Psychosocial Factors

Ongoing stressors — chronic relationship conflict, financial instability, unprocessed trauma, or high-demand occupational environments — create a sustained biological stress load that medication alone may not fully overcome. Depression does not occur in a vacuum, and treatment that doesn’t account for the full clinical picture tends to produce partial results at best.

Evidence-Based Next Steps: Augmentation and Combination Strategies

When an initial antidepressant has not produced adequate response, the next move is not simply to try a third antidepressant from the same class. There are structured strategies that have a meaningful evidence base, and they are worth understanding before your next appointment.

Augmentation Therapy

Augmentation means adding a second medication to an existing antidepressant that has shown partial benefit. The goal is to enhance or complete the response rather than starting over entirely. According to research published in PubMed Central on augmentation strategies for treatment-resistant depression, commonly used augmentation agents include atypical antipsychotics, lithium, and thyroid hormone, among others.

Each of these works through a different mechanism. Atypical antipsychotics, for example, can broaden the receptor activity of an existing antidepressant. Lithium has a long history in augmentation and remains clinically relevant. The choice of augmentation agent is individualized based on symptom profile, tolerability history, and the specific antidepressant already in use — this is not a one-size-fits-all decision.

Combination Antidepressant Therapy

Another approach involves combining two antidepressants with complementary mechanisms. For example, pairing an SSRI with a medication that acts on norepinephrine or dopamine pathways can address neurotransmitter targets that the first medication alone was not covering. This requires careful attention to drug interactions and individual tolerability, which is why this kind of adjustment belongs with a psychiatric provider rather than a primary care visit.

Psychotherapy as a Clinical Partner

Evidence-based psychotherapy — particularly cognitive behavioral therapy (CBT) — is not simply an add-on to medication. For treatment-resistant presentations, combining structured psychotherapy with medication management consistently outperforms either approach alone in the clinical literature. If therapy has not been part of the treatment plan, that gap is worth addressing directly.

Newer Interventional Options: Esketamine, TMS, and Beyond

Beyond adjustments to oral medication, there are interventional treatment options with strong evidence that are now accessible to more patients than they were even a few years ago.

Esketamine (Spravato)

Esketamine — a nasal spray derived from ketamine — represents one of the most significant advances in TRD treatment in recent decades. In 2019, the FDA approved esketamine nasal spray specifically for treatment-resistant depression in adults, marking the first genuinely new mechanism approved for depression in decades. Unlike traditional antidepressants, which primarily work on serotonin, dopamine, or norepinephrine systems, esketamine acts on NMDA glutamate receptors — a fundamentally different pathway.

The clinical significance is notable: some patients experience meaningful symptom relief within hours or days rather than weeks. It is administered in a certified healthcare setting under observation, not taken at home independently. It is used alongside an oral antidepressant, not as a standalone replacement. It is not appropriate for everyone, and a careful risk-benefit evaluation is required — but for patients who have not responded to multiple medication trials, it represents a legitimate, FDA-approved option worth discussing with a psychiatric provider.

Transcranial Magnetic Stimulation (TMS)

TMS is a non-invasive procedure that uses magnetic fields to stimulate specific brain regions associated with mood regulation — primarily the left dorsolateral prefrontal cortex. It does not require anesthesia, does not involve electrical current through the brain, and has no systemic side effects associated with medications.

TMS has FDA clearance for major depressive disorder and is particularly considered for patients who have not responded to antidepressants or who cannot tolerate them. It is typically delivered in daily sessions over several weeks. Response rates vary, but there is a meaningful body of clinical evidence supporting its use in TRD, and it is increasingly available through outpatient settings.

Electroconvulsive Therapy (ECT)

ECT carries outdated cultural stigma that does not reflect how it is actually practiced today. For severe, treatment-resistant depression — particularly cases involving psychosis, catatonia, or acute suicidality — ECT has one of the strongest evidence bases in all of psychiatric medicine. It is not a first-line approach, but for the right clinical presentation, it is a meaningful option.

How a Thorough Diagnostic Review Can Change the Treatment Plan

One of the most clinically consequential steps in addressing treatment-resistant depression is ensuring the diagnosis itself is accurate and complete. This sounds straightforward, but in practice, it often doesn’t happen — especially when earlier treatment occurred in rushed primary care settings or brief psychiatric appointments.

A thorough diagnostic review looks at several dimensions at once:

• Mood disorder subtype: Unipolar depression and bipolar depression require meaningfully different treatment approaches. Antidepressants used without a mood stabilizer in bipolar depression can worsen cycling and instability rather than helping.
• Co-occurring anxiety disorders: Anxiety and depression frequently co-occur, and untreated anxiety can significantly limit antidepressant response. Understanding whether what you’re experiencing is primarily depression, anxiety, or both changes the treatment architecture. This distinction matters more than most patients realize — if you’re unsure what you’re actually dealing with, this article on Is What You Are Feeling Stress, or Is It Actually Anxiety? lays out the differences clearly.
• ADHD: Adult ADHD is frequently missed, particularly in high-functioning adults who have developed compensatory strategies over years. ADHD and depression share overlapping features and frequently co-occur. When ADHD goes undiagnosed, treatment for depression alone tends to produce incomplete results. Psychiatric medication management that addresses both conditions requires a provider who evaluates the full picture.
• Trauma history: Significant trauma — particularly developmental trauma or PTSD — can present as depression while requiring a different clinical approach, including trauma-focused therapy, to produce meaningful change.
• Relevant medical history: Thyroid function, metabolic panels, sleep evaluation, and medication review can surface contributors that are sustaining symptoms despite adequate psychiatric treatment.

A complete psychiatric evaluation that covers this ground is not optional when antidepressants haven’t worked — it is the foundation of what comes next. Understanding what that process involves is a useful starting point, and this overview of What Happens During a Psychiatric Evaluation explains it clearly.

What to Expect When Working With a Psychiatric Provider on Treatment-Resistant Depression

If previous psychiatric experiences have felt rushed, unclear, or unproductive, it is worth knowing what a structured approach to TRD actually looks like — so you can recognize it and ask for it.

A Review of What Has Already Been Tried

A thorough evaluation starts with a careful review of every medication you have taken: the dose, the duration, the reason for stopping, and what your actual experience was on it. This history is diagnostic data. It tells a clinician a great deal about what mechanisms may or may not be working, and it prevents the common frustration of cycling back through medications that have already been shown not to work for you.

A Structured, Explainable Treatment Plan

Every next step in the treatment plan should come with a clear clinical rationale you can understand. Why this medication or intervention? What is it targeting? What does a reasonable response look like, and on what timeline? What are the relevant side effects to watch for? These are not complicated questions to answer — and if a provider cannot or does not answer them, that is a meaningful signal about the quality of care you are receiving.

Measurement-Based Care

Effective psychiatric medication management for TRD uses validated tools to track symptom severity over time — not just a general check-in about how you feel. Measurement-based care allows both patient and provider to evaluate response objectively, make data-informed adjustments, and avoid the pattern of vague, open-ended trials that produce ambiguous results.

Reasonable Timelines and Honest Communication

Some options, like esketamine, can produce early effects. Others, like augmentation with a new agent, may require several weeks to assess. A good provider will be transparent about those timelines and will schedule follow-ups at intervals that actually make clinical sense — not six months apart when an adjustment has just been made.

A Provider Who Takes Time

This is not a soft consideration — it is a clinical one. TRD requires more than a 10-minute appointment. It requires a provider who has the time and training to hold the full complexity of your history, identify what previous approaches missed, and construct a treatment plan that reflects that depth. For many patients, particularly working professionals, veterans, and first responders who have navigated high-demand systems, finding that level of care has historically been difficult. That difficulty is real, and it is worth seeking out settings designed specifically to provide it.

Moving Forward Without Starting Over

Treatment-resistant depression is not the end of the road. It is a clinical signal that the approach needs to become more precise, more individualized, and more comprehensive. The National Institute of Mental Health continues to invest significantly in TRD research because it is a recognized and solvable clinical challenge — not an outlier or an anomaly.

What changes the outcome is not simply trying more medications. It is working with a provider who has the training and the structure to evaluate what has and hasn’t been tried, identify what may have been missed, and apply a coherent, evidence-based strategy going forward. That is a different kind of appointment than what most people with TRD have experienced. It is also exactly the kind of appointment that can produce a different kind of result.

If you have been through multiple antidepressant trials without meaningful improvement, it makes sense to seek a comprehensive evaluation before your next medication change. That evaluation is where the real work begins — and it is available.

Frequently Asked Questions About Treatment-Resistant Depression

How many antidepressants do I need to try before it’s considered treatment-resistant?

The standard clinical threshold is two adequate antidepressant trials — meaning appropriate doses taken for sufficient duration, typically six to eight weeks or more. If two trials have not produced meaningful improvement, that meets the general definition of treatment-resistant depression and warrants a more structured clinical evaluation.

Can treatment-resistant depression get better?

Yes. TRD is not a permanent diagnosis. It describes a clinical pattern that requires a different approach — not an untreatable condition. Many patients with TRD do achieve meaningful improvement with augmentation strategies, interventional options like esketamine or TMS, or a corrected underlying diagnosis. The outcome is tied closely to the thoroughness of the evaluation and the range of options considered.

Is esketamine covered by insurance?

Coverage varies by plan and insurer. Esketamine (Spravato) has FDA approval specifically for treatment-resistant depression, and many insurance plans do cover it — particularly when documented trials of other antidepressants are on record. A psychiatric provider familiar with this process can help with prior authorization and documentation requirements.

What is the difference between augmentation and switching antidepressants?

Switching means stopping the current antidepressant and starting a different one. Augmentation means adding a second medication to the existing one, typically when there has been partial but incomplete response. Which strategy makes more sense depends on how much benefit, if any, the current medication has provided and what the overall treatment history looks like. Both are legitimate clinical approaches — the choice should be based on individual history, not convenience.

Should I be seeing a psychiatric physician instead of my primary care provider for TRD?

For straightforward depression, primary care management can be appropriate. For treatment-resistant depression, the complexity typically warrants psychiatric provider-level evaluation — someone with specialized training in diagnostic nuance, psychiatric medication management, and the full range of TRD-specific treatment options. Primary care providers have limited time and may not have access to the full range of interventional options or the ability to conduct a comprehensive diagnostic review.